Related Experiment Video
Updated: Jan 14, 2026
05:55
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
908
[Glucocorticoid-induced osteoporosis, up to date]
1Department of Biofunctional Research, National Institute for Longevity Sciences.
Clinical Calcium
|March 19, 2005
Summary
Glucocorticoid-induced osteoporosis (GIO) increases fracture risk, especially in vertebrae, even after medication stops. New management strategies now consider factors beyond bone density for GIO.
Area of Science:
- Endocrinology and Bone Metabolism
Context:
- Glucocorticoid-induced osteoporosis (GIO) is a significant clinical concern.
- Glucocorticoids (GC) elevate fracture risk, particularly affecting vertebral bones.
- Fracture risk persists post-GC cessation, remaining higher than in non-medicated individuals.
Purpose:
- To review current understanding and management of GIO.
- To highlight evolving GIO management strategies incorporating new knowledge.
- To underscore the need for further research and development in GIO.
Summary:
- GC treatment dose-dependently increases fracture risk.
- Bone mineral density thresholds for fracture prediction are higher in GIO compared to post-menopausal osteoporosis.
- Recent UK management guidelines for GIO incorporate risk factors beyond bone mineral density.
Impact:
- Updated GIO management reflects new scientific insights.
- Consideration of broader risk factors improves GIO assessment.
- Anticipation of new Japanese management guidelines indicates global focus on GIO.
- Further research is crucial for advancing GIO prevention and treatment.
